misleading statements

Rosen Law Firm urges PomDoctor Ltd. investors with losses exceeding $100K to file securities claims by April 7, 2026, alleging fraud via social media misinformation and insider selling.

Vital Farms faces class action lawsuit over alleged ERP system misstatements that caused missed earnings targets between May 2025 and February 2026.

Rosen Law Firm seeks lead plaintiffs in securities class action against $RARE over alleged misleading statements regarding setrusumab's efficacy in treating osteogenesis imperfecta.

Class action lawsuit filed against Vital Farms for allegedly concealing ERP system delays that caused the company to miss 2025 earnings guidance, affecting investors from May 2025 through February 2026.

Class action filed against $INO alleging executives made false statements about CELLECTRA device manufacturing and INO-3107 regulatory timeline between October 2023 and December 2025.

REGENXBIO ($RGNX) sued for alleged securities violations involving undisclosed adverse trial data on RGX-111 candidate after FDA clinical hold.

Schall Law Firm seeks lead plaintiffs in class action against $QURE for alleged false statements regarding FDA approval timeline and BLA submission misrepresentations.

Rosen Law Firm filed class action against Concorde International Group alleging false statements and fraudulent disclosures. Investors have until May 20, 2026 to serve as lead plaintiff.

Ultragenyx Pharmaceutical faces securities fraud lawsuit alleging misrepresentations of setrusumab trial results and inadequate risk disclosures to investors.

Rosen Law Firm files class action against $IBRX, alleging founder Patrick Soon-Shiong overstated Anktiva capabilities, misleading investors about company prospects.

Rosen Law Firm sues Atara Biotherapeutics for allegedly misrepresenting tabelecleucel drug's regulatory prospects and manufacturing capabilities to investors between May 2024 and January 2026. Lead plaintiff deadline set for May 22, 2026.

$POM investors have until April 7, 2026 to join class action alleging fraud involving fake promotions, insider trading, and market manipulation.

Class action lawsuit filed against Concorde International Group ($CIGL) alleges fraudulent stock promotion scheme involving fake promoters, insider dumping via offshore accounts, and coordinated social media misinformation during April-July 2025. Claim deadline: May 18, 2026.

$PSIX faces securities fraud lawsuit alleging overstated data center demand and understated manufacturing costs between May 2025-March 2026. Shareholders can join by May 19, 2026.

Rosen Law Firm urges $PMI investors to join class action over alleged fraudulent stock promotion scheme involving social media misinformation and insider dumping.

Hagens Berman investigates $QURE over FDA allegations of misrepresented gene therapy data and manipulated study design. Stock tumbled 49% following November 3 FDA rebuttal.

Hagens Berman sues $CORT over alleged concealment of FDA warnings on relacorilant. Stock crashed 50% following Complete Response Letter, erasing $2.5B in market value.

Bragar Eagel & Squire announces class action lawsuit against Concorde International ($CIGL) for alleged stock fraud involving social media misinformation, fake financial professionals, and insider dumping.

Class action lawsuit filed against $PSIX alleging false statements about data center sales capture and understated manufacturing costs. Investor deadline set for May 19, 2026.

Class action lawsuit alleges $PSIX made false statements about data center demand and understated manufacturing costs, covering May 2025-March 2026 investors.